The health of Elixinol Global (ASX:EXL) doesn’t tie directly to the medical cannabis market in Australia, but it does offer a clearer picture on the progress of this sector.

The company offers labelled products, along with bulk and wholesale hemp-derived cannabidiol (CBD), around the world. Its offerings have a variety of health- and wellness-related uses.


Though it’s based in Australia, Elixinol operates heavily in the US, selling hemp-derived CBD products.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

The US hemp industry has become attractive for CBD-focused companies, thanks in large part to regulatory moves that have changed how the country’s federal government views hemp.

In an exclusive interview with the Investing News Network (INN) during the recent MJBizCon event in Las Vegas, Nevada, Leif Harrison, CEO of the American division for Elixinol, explained that due to the global nature of the marijuana industry, potential investors are not deterred by the company’s ASX listing.

The executive added that although marijuana and hemp investment have stuck closer to the Canadian capital markets, US investors interested in the cannabis plant have also seen their horizons expanded.

“This doesn’t feel like (a) traditional US homegrown public entity … I don’t think it surprises anybody at this point,” Harrison said.

The executive added that, in his estimation, Elixinol’s US assets account for a leading portion of the company’s revenue. As such, it falls on them to support the firm’s expansion plans. And because the firm has operations worldwide it must also keep communication open to maintain its direction.

The health of Elixinol Global: Challenges in Japan

A crack in this system showed last year for the company’s division in Japan. In October, Elixinol told investors it had discovered a breach in its compliance standards out of Elixinol Japan.

The issue, which caused the company to launch an internal investigation, was due to the sourcing of CBD used in its products.

“The non-compliance relates to the strict requirements in Japan on sourcing CBD from only hemp stalk and seed,” the company said in a statement.

Harrison explained to INN that the international ventures of the firm are more likely to get fed hemp-derived CBD products from the US. This led to a mismatch in the regulation standards since the company makes its products from flowers and leaves.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

“Until we can set up local production based on local rules, then we’re out of that market until we get back in the right way,” Harrison said.

In December, the parent company confirmed it had sold over half of its stake in Elixinol Japan.

“We have made an important decision to move to a licensing model for Japan and to press ahead with our growth priorities in our key markets,” Andrew Duff, chairman of Elixinol, said at the time.

The health of Elixinol Global: Investor takeaway

So far in 2020, Elixinol has seen the value of its shares rise steadily as it tries to regroup from a difficult 2019 for itself and the financial space at large. During the year, the firm saw its value drop by nearly 80 percent on the ASX.

Shares of Elixinol had bounced back by over 20 percent in value by the start of February 2020.

Despite the challenges presented to the global cannabis investment market last year, experts agree 2020 may be poised to offer alternative takes on the market with a bigger spotlight on investors.

Cameron Bell, an analyst with Canaccord Genuity Australia, issued a note to investors highlighting how investors’ concerns about the industry may be easing up, including in the burgeoning Australian market.

“The strength has been partially led by investor sentiment in offshore markets, as some key concerns have eased while expectations for demand growth remain very high and access to funding improves,” Bell wrote in his note.

Elixinol is a leading name in Canaccord’s own Australian Cannabis Index based on its market cap.

For more on Elixinol, listen below to INN’s interview with Joy Beckerman, the company’s regulatory officer and industry liaison, at last year’s MJBizConINT’L event in Toronto, Ontario.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated May 25, 2021 were elected as directors of the Company at Avicanna‘s annual general meeting of shareholders held on June 24, 2021 (the ” Meeting “). The detailed results of the vote for the election of directors held at the Meeting are set out below.

Keep reading... Show less

Quantum 1 Cannabis (CSE:QQ) announced its revenue for the third quarter of 2021 has increased by 672 percent and gross profit has increased by 463 percent compared with the same quarter in 2020. Quantum 1 Cannabis CEO Russ Rossi expounded on this exponential growth and what’s behind this remarkable leap. 

“We had an opportunity during our cannabis training to opt into some leases for cannabis retail. So we thought, let’s take a shot at this and see if we can use our experience with mobile location and supercharge. It paid off. It was a new game for everybody. It’s a lot of luck when opportunity meets preparation,” said Rossi. 

Quantum 1 Cannabis attributed the growth to high month-over-month sales coming from its flagship store in North Vancouver, improved demand for specialized “cottage-grown” sativa and indica products, continued training and hiring of best-of-breed staff and management to cater to consumer inquiries and expanded in-house technology for management of human resources, inventory and regulatory requirements. 

“Our plan is to have the maximum number of retail stores possible in British Columbia. We have 10 year leases on these stores, putting everything in on a solid pitch for the city council. I’m pretty confident that we’re going to have eight centers full blast in BC within six months,” explained Rossi. 

Quantum 1 Cannabis has signed a memorandum of understanding to acquire an approved municipal cannabis retail location in one of Vancouver’s most diverse neighborhoods at 41st Avenue and Cambie Street in Vancouver, British Columbia. The flagship location is expected to expand the company’s footprint in the Lower Mainland.

Watch the full interview with Quantum 1 Cannabis (CSE:QQ) CEO Russ Rossi above.

Keep reading... Show less

Process leads to standardized psychedelic extracts that are reproducible, scalable, cost-effective and commercially viable

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a process that dramatically increases the production of therapeutics for use in psychedelic-assisted psychotherapy.

Keep reading... Show less

Opening Marks Company’s 107th Retail Location Nationwide

Strategic Expansion Will Help Serve the State’s Rapidly Growing Cannabis Market

Keep reading... Show less

Ayurcann (CSE:AYUR) entered into a joint venture with Bazelet Group, Israel’s largest privately held medical cannabis company. Ayurcann CEO Igal Sudman shared the company’s excitement about bringing unique terpene-enriched medicinal cannabis to the Canadian marketplace. 

“Canada is a very closed-loop country, and the opportunity to bring a variety of different enhancement and technologically advanced products is very important to us. The relationship that we formed with Bazelet is going to enhance our offerings into the Canadian marketplace,” Sudman said. 

Bazelet has launched multiple lines of terpene-enriched cannabis oils; each one is specifically designed for various indications, symptoms and personal needs. The company’s terpene-enriched products are optimized for women’s health, for elderly population needs, for specific types of pains (muscle, joint, neuropathic) and for improved night sleep. 

According to Sudman, there are a lot of larger companies that have tried to do this, but none have been able to successfully bring innovation into the market. Ayurcann is rapidly forging partnerships with several companies worldwide, including Cannmart, Patient Choice and Kindred Partners.

“We’re growing the business, customer base, relationships and partnerships worldwide. We’re bringing the latest technology into Canada, and enhancing not only our company, but the investors’ value moving forward,” added Sudman. 

Watch the full interview with Ayurcann CEO Igal Sudman above.

Keep reading... Show less